Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors gave Lycurim to 30 patients with malignant lymphoma (LLC--12 cases, Hodgkin's disease - 15 cases, reticulosarcoma - 2 cases and lymphosarcoma - 1 case). The patients were divided into three groups. Group I received only Lycurim, group II - Lycurim and prednisone, group III - Lycurim and Solcoseryl. Significant improvement was observed in 22 patients, with complete remission in 5 cases and partial in 17 cases. Leucopenia and thrombocytopenia precluding treatment were never observed in cases treated simultaneously with prednisone or Solcoseryl. The authors believe that the proportion of remissions may be increased combining Lycurim with vincristine, procarbazine and glycocorticosteroids (LOP or LOPP).
 ...
PMID:[Preliminary observations on the results of treating malignant lymphoma with Lycurim]. 20 51

Tumorigenicity of lymphoid cell lines of different origin upon xenotransplantation (s.c. and i.m.) in cell concentrations of 1 X 10(6) cell/inoculum into nude mice was correlated to karyotype, presence of the 14 q + marker, EBV reactivity and immunological markers. Lymphoblastoid cell lines (LCL), lacking the 14 q + marker failed to produce tumors independent upon diploidy or aneuploidy. Lymphoma-type lines of Burkitt lymphoma, lymphosarcoma and Hodgkins disease-origin, genotypically aneuploid, and expressing the 14 q + marker were tumorogenic in nude mice, when inoculated in the same cell quantities where LCL failed to form tumors. Tumorgrowth in nude mice was independent upon the presence of EBV in the inoculated cells.
 ...
PMID:Lymphoid cell lines: in vitro cell markers in correlation to tumorigenicity in nude mice. 20 50

The anti-complement immunofluorescence (ACIF) method was used to demonstrate EBNA in B lymphocytes separated from the peripheral blood of patients with infectious mononucleosis (IM) or other diseases. In the acute phase of IM of Epstein-Barr virus (EBV) origin, 0.5--1% of the B lymphocytes proved to be positive in 6 of the 8 patients tested. In two of the positive cases the test was repeated 20 and 26 days, respectively, after clinical symptoms had appeared; the result was negative in both cases. No EBNA-positive cells were found in the peripheral blood of 17 patients with Hodgkin disease, 3 with systemic lupus erythematosus and 2 with lymphosarcoma. It is supposed that EBNA-positive cells appear in detectable amount exclusively in the acute phase of EBV infection.
 ...
PMID:Cells containing Epstein--Barr nuclear antigen (EBNA) in peripheral blood. 22 32

Salivary obstruction may result from growth of a malignant tumor in the vicinity of the salivary gland, as well as result from sialolithiasis. Lymphomas of all types, including Hodgkin disease, lymphosarcoma, and reticulum cell sarcoma frequently are diagnosed in the region of the head and neck. The biopsy of a suspected tumor should be done by multiple needle biopsies. Open biopsies should be avoided to prevent seeding and spreading. When the diagnosis of malignant lymphoma is made, the tumor must be classified histologically and the extent of disease must be determined and staged for proper treatment. Treatment should consist of radiation and chemotherapy. Surgery is of little value. Malignant lymphomas usually are disseminated widely and end fatally.
 ...
PMID:Malignant lymphoma and salivary obstruction. 27 57

Vindesine is a derivative of vinblastine and of vincristine. A high proportion of remissions were obtained in acute lymphoid leukaemia (6 complete and 1 incomplete remissions in 15 patients), in blastic crisis of chronic myeloid leukaemia, and a few responses have been registered in lymphosarcoma and Hodgkin's disease. Permanent 48 h i.v. infusion may include a remission where i.v. pusch of the same dose has failed. The most remarkable characteristic of vindesine is the absence of cross-resistance with vincristine as documented in acute lymphoid leukaemia.
 ...
PMID:[Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)]. 27 88

When ficoll purified peripheral blood lymphocytes were treated with fluorescein conjugated lectins from lentils (LCH), castor beans (RCA) and phaseolus coccineus beans (L-and E-PHA) for 15 min and the percentages of the cap forming cells were examined, the values of leukemic lymphocytes were reduced compared to the values obtained with normal lymphocytes. The reduction was more than half in patients with acute and chronic myelogenous leukemia and immunoblastoma, it was only one quarter in patients with chronic lymphocytic leukemia, Hodgkin's disease and lymphosarcoma. The lowest number of cap forming cells was found in lymphoblasts of established lymphoblastoid cell lines. The four different lectins showed nearly the same capacity in the induction of caps. After successive binding, the different lectins showed cocapping on the lymphocyte surface.
 ...
PMID:Cap formation on lymphocytes from patients with leukemic diseases induced by four different lectins. 27 61

Vindesine, an analog of vinblastine and vincristine, has been submitted to a phase II trial, the results of which are judged in terms of remission induction. A high proportion of remissions were obtained in acute lymphoid leukemia and blastic crisis of chronic myeloid leukemia, and a few responses have been registered in lymphosarcoma and Hodgkin's disease. A continuous 48-hour iv infusion may induce a remission where an iv push of the same dose has failed. The most remarkable characteristic of vindesine is the absence of cross-resistance with vincristine as documented in acute lymphoid leukemia.
 ...
PMID:Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine. 27 96

The diseases discussed in this paper include chronic lymphocytic leukemia, monocytic leukemia, chronic granulocytic leukemia, acute leukemias, Hodgkin's disease, and lymphosarcoma. Cutaneous manifestations of these disorders are often sufficiently different to indicate a certain leukemia or lymphoma. The cutaneous manifestations of leukemias and lymphomas may help the clinician suspect the diagnosis.
 ...
PMID:Skin manifestations of leukemias and lymphomas. 27 26

Vindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proportion of complete (36%) and over 50% partial regressions were obtained in acute lymphoid leukemias (ALL) (overall response 63%) whatever the perceptible phase, in blastic crisis of chronic myeloid luekemia (55%), and some responses were recorded in lymphosarcoma (40%). No effect has so far been seen in acute myeloid keukemia or in Hodgkin's disease. Malignant neoplasms of the immunoblastic type seem to be particularly sensitive to VDS. Continuous 48 h IV infusion can induce a remission where an IV push administration of the same dose has failed. One remarkable characteristic of VDS is the apparent absence of cross-resistance with VCR: in acute leukemic forms, 55% of patients who failed to obtain remission induction after three weekly injections of VCR (used in combination chemotherapy) achieved a complete or partial remission with VDS. The toxicity was mainly neurologic (paralytic ileus, constipation, paresthesias, loss of reflexes) and hematologic (leukopenia and thrombopenia), and was not more significant than with the other agents: four patients died of infection or hemorrhage.
 ...
PMID:Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. 28 69

Despite the incomparability in the reporting of leukemia and lymphoma incidence among populations and the relative rarity of these diseases, real differences in rates are discernible from available data. In general, the incidence of each of the leukemias and lymphomas is lower in Japan than in other Pacific rim populations whose rates are known. Particularly striking is the low incidence of CLL in Japan. Among Japanese in Hawaii, rates of some of these cancers (lymphosarcoma, CML) approach those of whites, whereas rates of other cancers (Hodgkin's disease, multiple myeloma, ALL, CLL, and AML) more closely resemble those of native Japanese. The number of Chinese living in countries served by population-based cancer reporting systems is too small for any firm conclusions to be made about leukemia and lymphoma incidence in this group. The incidence of these diseases in certain other nonwhite Pacific rim residents (i.e., Mexican Americans, blacks, and Maoris) is, by and large, similar to that of whites.
 ...
PMID:Geographical variation in the incidence of the leukemias and lymphomas. 29 90


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>